We evaluated the presenting characteristics, response to therapy, and outcome for 46 patients infected with Mycobacterium kansasii and human immunodeficiency virus (HIV). M. kansasii infection occurred late in HIV disease (mean CD4 lymphocyte count, 52.4/mm 3 ), when most patients had already developed AIDS; 91.3% of the patients had pulmonary involvement, and 21.7% had disseminated disease. Clinical and radiographic findings were consistent with pulmonary disease and had been present for Ç4 weeks. Fourteen of the treated patients had disease that resolved or abated (mean survival {SE, 73.7 weeks { 14.6 weeks), and 13 had disease that persisted unchanged or worsened (mean survival {SE, 57.3 { 15.8 weeks). The outcome was poor for 17 patients who did not receive effective therapy (mean survival { SE, 14.1 { 5.3 weeks). M. kansasii infection presents late in the course of HIV disease, and the lung is the organ most frequently involved. Survival is clearly influenced by therapy, and even patients who respond poorly to therapy survive longer than those who are not treated. we defined pulmonary M. kansasii infection as a process in Of patients with AIDS whose cases were reported to the which there was radiographic evidence of pulmonary disease Centers for Disease Control and Prevention (CDC) between that could not be attributed to other causes and in which multi-1981 and 1987, 0.44% of those from areas where M. kansasii ple colonies of M. kansasii were isolated from respiratory tract is endemic and 0.08% of those from areas where M. kansasii specimens on at least two occasions and/or from a closedis not endemic had disseminated M. kansasii infection [6], lesion specimen that had been collected in a sterile fashion. and there is a growing body of literature that has documented Disseminated M. kansasii infection was defined as isolation of the association between HIV and M. kansasii infections M. kansasii from a site other than, or in addition to, the lungs, [8 -13].
Mycobacterium kansasii causes pulmonary disease in pa-
Patients and Methods tients with different forms of preexisting pulmonary disease, This study was conducted at Jackson Memorial Hospital, a and this organism causes disseminated, extrapulmonary disease 1,500-bed facility in Miami that is the main teaching hospital in patients with various immunodeficiencies and systemic illof the University of Miami School of Medicine. There are nesses [1 -5] . M. kansasii is second only to Mycobacterium Ç3,000 HIV-related admissions and 22,000 HIV-related outpaavium complex among the atypical mycobacteria that cause tient visits at this center annually. disease in patients with AIDS [6] , and disseminated M. kansasii Case definitions and classification of outcome. On the basis infection is an AIDS-defining condition in patients infected of the criteria of the American Thoracic Society (ATS) [15] , with HIV [7] .
we defined pulmonary M. kansasii infection as a process in Of patients with AIDS whose cases were reported to the which there was radiographic evidence of pulmonary disease Centers for Disease Control and Prevention (CDC) between that could not be attributed to other causes and in which multi-1981 and 1987, 0.44% of those from areas where M. kansasii ple colonies of M. kansasii were isolated from respiratory tract is endemic and 0.08% of those from areas where M. kansasii specimens on at least two occasions and/or from a closedis not endemic had disseminated M. kansasii infection [6] , lesion specimen that had been collected in a sterile fashion. and there is a growing body of literature that has documented Disseminated M. kansasii infection was defined as isolation of the association between HIV and M. kansasii infections M. kansasii from a site other than, or in addition to, the lungs, [8 -13] .
skin, or hilar lymph nodes [7] . Effective therapy was defined In the United States, M. kansasii is most frequently isoas a 4-week course of a combination antimycobacterial regimen lated in Louisiana, Illinois, Texas, and Florida [14] . Herein, that consisted of at least two antibiotics with predictable activwe describe the clinical and radiographic characteristics of ity against M. kansasii. Outcome was defined as cure (complete M. kansasii disease in 46 HIV-infected patients seen at our resolution of all symptoms and radiographic findings), imcenter in South Florida, and we describe the clinical courses, provement (partial resolution of symptoms and abatement of responses to therapy, and outcomes for these patients. radiographic findings), persistence (lack of significant change in the severity of symptoms or radiographic abnormalities), and worsening (symptomatic and radiographic deterioration). Data collection and statistical analysis. We reviewed the (ELISA and western blot assay and/or immunofluorescence For 14 (53.9%) of the 26 patients known to have AIDS, M. kansasii infection was the only opportunistic infection presassay) or fulfillment of CDC criteria for AIDS [7] . The other nine patients were known to be seronegative for HIV, or their ent; the remaining 12 patients (46.1%) had an additional opportunistic infection (table 1) . Nine of the 14 patients without HIV status was unknown, and they are not included in this analysis.
another infection were not known to be infected with HIV. M. kansasii was the only infection in 13 (65%) of the 20 patients We used standardized forms to retrieve demographic, clinical, laboratory, radiographic, and microbiological information without a prior diagnosis of AIDS, whereas seven (35%) had another opportunistic infection or a malignancy (table 1) were Hispanic, and four (8.7%) were non-Hispanic whites.
Pulmonary lymphoma 1 (2.2)
These demographic characteristics were similar to those of the Source of M. kansasii isolates (no. of isolates)
general HIV-infected population seen at our center. ).
Only one patient had a CD4 lymphocyte count of ú200/mm 3 . Response to therapy and outcome. Two patients were lost to follow-up immediately after discharge, and the other 44 with localized pulmonary disease (59.5/mm 3 ) and that for patients with disseminated disease (20.9/mm 3 ) were not signifipatients were followed up for a mean period ({SE) of 36.3 { 7 weeks (range, 0 -156 weeks). Thirty-seven patients received cantly different (P Å .08).
All 46 patients whose records we reviewed were symptomsome form of therapy with activity against M. kansasii for varying periods (table 3) , but only 27 patients received treatatic and had been hospitalized by the time the diagnosis of M. kansasii disease was made; however, to determine the charment for a sufficient period to meet our definition of effective therapy. Sixteen of these 27 patients were compliant with their acteristic symptomatology of M. kansasii disease in patients with HIV infection, we evaluated the symptoms of only those therapeutic regimens; however, the other 11 missed at least 50% of their doses between clinic appointments. 26 patients whose sole opportunistic infection was due to M. kansasii (table 2) . There were 24 cases of pulmonary infection Eight patients (six, compliant; two, noncompliant) were cured of their disease, and six patients (all compliant) had (two patients also had diarrhea, and one had axillary adenitis) and one case each of supraclavicular adenitis and bacteremia.
disease that had abated by the time of their last evaluations. Four patients were eventually lost to follow-up. ({SE) of treatment was 27.7 { 6.2 weeks (range, 4 -53 weeks). All but one of the patients died, but M. kansasii was not believed to be the cause of death for any of these patients. Thirteen patients (four, compliant; nine, noncompliant) re- reported in the literature [8, 12, 13] . Of the 20 patients without a prior diagnosis of AIDS for whom CD4 lymphocyte counts were available, 19 had counts low enough to meet the 1993 There was no difference in the survival of patients according CDC criteria for AIDS [7] . Thus, M. kansasii is similar to to compliance with therapy (data not shown). There was a M. avium complex in that M. kansasii causes infection in HIVtendency towards longer survival among patients with localized infected patients with increasing frequency as the immunosuppulmonary disease (mean survival [{SE], 52.1 { 9.5 weeks; pression progresses [18] . range, 0.4 -156 weeks) than among those with disseminated M. kansasii causes significant disease in the absence of other disease (mean survival [{SE], 22.8 { 7.7 weeks; range, pathogens. Twenty-seven (58.7%) of our 46 patients had symp-0 -73 weeks), but this difference was not significant (P Å toms caused exclusively by M. kansasii. In fact, HIV infection .2). The mean survival ({SE) among patients with another was diagnosed in nine patients (19.6%) solely because of sympopportunistic infection at the time that M. kansasii infection toms caused by the M. kansasii infection, and HIV infection was diagnosed (24.4 { 7.5 weeks; range, 0 -91 weeks) was was diagnosed in 14 patients (30.4%) without a previous diagshorter than the mean survival ({SE) among patients without nosis of AIDS because of symptoms caused exclusively by another opportunistic infection (57.5 { 10.5 weeks; range, M. kansasii. Although it is disseminated infection rather than 1 -156 weeks) (P Å .003).
pulmonary M. kansasii infection that is considered an AIDSdefining illness [7] , all 14 patients in this latter group had M. kansasii pulmonary disease; thus this condition should perDiscussion haps be considered AIDS-defining regardless of the CD4 lymphocyte count. In several recent series of patients infected with HIV and M. kansasii, relatively small numbers of patients have been described, or the strict criteria proposed by the ATS were not used to distinguish between disease and colonization with atypical mycobacteria. Some of these series have even included patients with single M. kansasii isolates [9, 12, 13] . The applicability of the ATS criteria for diagnosing nontuberculous mycobacterial infections in patients who have such compromised immune systems as do HIV-infected patients is controversial [13, 17] . In fact, it has been argued that a single M. kansasii respiratory isolate in a patient with HIV infection should be considered indicative of disease [13] .
In our view, the clinical presentation and outcome for some HIV-infected individuals with single respiratory isolates of M. kansasii are such that the diagnosis of pulmonary disease is unquestionable, but this is not invariably the case for all One recent report identified a strain of M. kansasii that is therapeutic regimens, compliance, and duration of treatment, therapy increased survival, even when given for relatively short isolated with greater frequency from HIV-infected individuals than from other individuals with M. kansasii disease [19] . It periods. This effect was evident for the entire group of treated patients, including those for whom therapy was believed to has been postulated that this HIV-associated strain may be less virulent than other strains and that it may be capable of causing have failed, but this effect was most prominent for patients who were cured or at least had abatement of the disease with disease only in the presence of significantly impaired cellular immunity.
treatment. Disseminated M. kansasii disease seems to follow a more One of our patients without a diagnosis of AIDS who had M. kansasii pulmonary infection had a CD4 lymphocyte count aggressive course than pulmonary disease and is associated with survival that is shorter than that for patients with disease of 234 cells/mm 3 . This patient would not meet the current diagnostic criteria for AIDS [7] , but the evidence presented in localized to the lung. Although this difference did not reach statistical significance, it is possible that with larger numbers this report and in others suggests that profound immunodeficiency is needed for M. kansasii to cause disease in patients of patients, the difference would have been significant. The survival for patients who were not compliant with therapy did infected with HIV. In our view, this patient should be regarded in the same way as a patient with HIV infection and a CD4 not seem to be shorter than that for compliant patients; thus, it is possible that even intermittent treatment of this condition lymphocyte count of ú200 cells/mm 3 who presents with an opportunistic infection, such as Pneumocystis carinii pneumois better than no treatment at all. At present, the recommendations of both the ATS and the nia, and would be considered to have AIDS, regardless of the CD4 lymphocyte count.
CDC (i.e., an 18-month course of combination antimycobacterial treatment) remain the best guidelines for the treatment of As reported elsewhere [8 -13], we found that the lung is the organ in which most M. kansasii infections occur, and M. kansasii disease in patients infected with HIV [25] , but optimum management remains to be determined on the basis disseminated disease is less frequent. Only 22% of our patients had disseminated disease (including that involving the lung); of a prospective trial. this percentage is lower than that reported in other series (i.e., 23% -56%) [8 -13] , most likely because of our equally low and ú50% of those who received õ4 weeks of therapy died During the period when the patients described in this paper 
